Uniphar Plc

Company report, featuring a PESTLE, Porters Five Forces, 5C, MOST, CATWOE and SWOT analysis

Introduction

This study of Uniphar Plc is part of our coverage of the 10,000 largest companies in the world. We create and update it at an accelerated rate to guarantee the content is as up-to-date as possible.

Premium members can access the full study on Uniphar Plc, including the SWOT analysis, PESTLE, 5C analysis, CATWOE, Porters Five Forces, MOST analysis, and a myriad of additional high value sections.

We identify potential new products and services, forecast future market trends, and predict synergies between Uniphar Plc and other organisations, apart from the sections driven by analysis.

Company Description

Uniphar Plc is a leading Irish healthcare services company, headquartered in Dublin, Ireland. Founded in 1980, the company provides a range of products and services to customers in Ireland and the UK. Its main products and services include pharmacy services, healthcare logistics, medical device distribution, medical technology, and specialty pharmacy services. Uniphar Plc serves the healthcare markets of Ireland, the UK, and other international markets.

Industry Overview

Uniphar Plc is a key player in the pharmaceutical services industry, with global annual revenues of $50 billion and over 2 million employees. The majority of Uniphar Plc's employees are located in Ireland, the UK, Italy, France, Germany, Spain, and the United States. Employees in the industry provide a range of services, including drug distribution, supply chain management, and drug manufacturing.

Industry Classification

In terms of formal classification, Platform Executive has tagged Uniphar Plc as a business operating within the Consumer industry.

1. Introduction
2. Company Description
3. Industry Overview
    3.1 Industry Classification
4. Intellectual Property
5. Major Products and Services
6. Key Competitors
7. Stakeholders
8. Value Proposition
9. Customers and Cohorts
10. Competitive Advantages
11. Market Trends
12. Key Performance Indicators
13. Financials (BETA)
    13.1 Highlights
    13.2. Board members
    13.3 Share Performance
    13.4 Income Statement
14. PESTLE Analysis
15. Potential Products/Services
16. Potential Synergies
17. Porter's Five Forces
18. CATWOE Analysis
19. SWOT Analysis
    19.1 Strengths
    19.2 Weaknesses
    19.3 Opportunities
    19.4 Threats
20. 5C Analysis
21. MOST Analysis
22. Innovation Scorecard
23. Appendices

Save to Library

Bookmark (0)

To login to your account click here.

Intellectual Property

Some of the Patents granted to, or relevant to the organisation include the following:

Patent Title: Aqueous pharmaceutical composition
Patent ID: WO2020033134A1
Date: 03/12/2020.

Patent Title: Method of treating a subject with a cns disorder
Patent ID: WO2020033133A1
Date: 03/12/2020.

Patent Title: Pharmaceutical compositions and methods of use
Patent ID: WO2020033132A1
Date: 03/12/2020.

Patent Title: Compositions and methods for treating a gastrointestinal disorder
Patent ID: WO2020033131A1
Date: 03/12/2020.

Patent Title: Solid pharmaceutical compositions of a glycoprotein
Patent ID: WO2020033130A1
Date: 03/12/2020.

Patent Title: composition for treating a neurological disorder
Patent ID: WO2020032628A1
Date: 03/05/2020.

Patent Title: Pharmaceutical composition for treating a neurological disorder
Patent ID: WO2020032627A1
Date: 03/05/2020.

Patent Title: Pharmaceutical compositions and methods of use
Patent ID: WO2020032626A1
Date: 03/05/2020.

Patent Title: Pharmaceutical compositions and methods of use
Patent ID: WO2020032625A1
Date: 03/05/2020.

Patent Title: Pharmaceutical compositions and methods of use
Patent ID: WO2020032624A1
Date: 03/05/2020.

Major Products & Services

The main products and/or services commercialised by this business include the following:

Pharmaceuticals
Medical Devices
Healthcare Supplies
Veterinary Supplies
Clinical Services
Homecare Services
Logistics Solutions
Specialty Services
Digital Solutions

Key Competitors

We have identified the following organisations as being key competitors:

McKesson Corporation
AmerisourceBergen Corporation
Walgreens Boots Alliance Inc
Cardinal Health Inc
Celesio AG
Alliance Healthcare
Alliance Pharmaceuticals Ltd
H.D. Smith Wholesale Drug Co.
United Drug plc
Sangers Ltd

Unlock this SWOT analysis report

Each detailed study features a PESTLE, Porters Five Forces, 5C, MOST, CATWOE and an expert SWOT analysis, along with a myriad of other sections.

Premium members have FULL ACCESS to this content and approximately 10,000 similar competitive intelligence reports.

Premium membership is just $195 per month, with annual membership at $1,950 / seat.

UNLOCK CONTENT

Key Stakeholders

Stakeholders are individuals or groups who have an interest in a business and/or are affected by its actions.

These stakeholders can have different requirements and expectations from the business, which must be taken into account when making decisions.

By understanding their stakeholders’ requirements, a business can make informed decisions that benefit all involved.

Below is the list of internal and external stakeholders we have identified for this business:

1. Customers: Uniphar Plc's customers include healthcare professionals, patients, and healthcare organisations.

2. Employees: Uniphar Plc's employees are responsible for delivering services and products to customers.

3. Suppliers: Uniphar Plc's suppliers provide the products and services that the company needs to operate.

4. Investors: Uniphar Plc's investors provide the capital needed to fund the business.

5. Government: Uniphar Plc is regulated by the government and must adhere to certain regulations.

6. Competitors: Uniphar Plc's competitors provide similar products and services, creating competition in the market.

Value Proposition

A value proposition explains the unique value and/or benefits that an organisation provides to its customers, partners, stakeholders and the overall market. It outlines what makes a company like Uniphar Plc different from its competitors, along with what it can offer that key competitors cannot.

A corporate value proposition can be used with the competitive advantages section of this report in order to better understand Uniphar Plc and its position within the marketplace.

Uniphar Plc is a global medical technology company that develops, manufactures and sells products and services in the fields of diagnostic imaging and medical information technology. The company's products and services are used by physicians and other healthcare professionals to diagnose and treat patients.

Competitive Advantages

Competitive advantages are unique attributes, strategies, resources, or capabilities that allow an organisation to outperform its competitors and achieve superior market position and profitability.

Competitive advantages for the business include the following:

Diverse portfolio: Uniphar Plc has a diverse portfolio of products and services including pharmaceuticals, medical devices, healthcare technology, medical nutrition, hospital services, home care, and over-the-counter products. This provides a competitive edge in the market as it allows them to cater to multiple customer needs.

Experienced Management Team: Uniphar has an experienced management team with extensive experience in the pharmaceutical and healthcare industry. This gives them an advantage in terms of understanding the customer needs and developing effective strategies to meet them.

Robust Distribution Network: Uniphar has a robust distribution network that is well established and covers the entire Irish market. This ensures that their products reach their customers quickly and efficiently.

Strong Brand Recognition: Uniphar has a strong brand recognition due to its long-standing presence in the market. This helps them gain customer loyalty and trust, which can be an important competitive advantage.

Innovative Technology: Uniphar has invested heavily in innovative technology such as RFID technology and automated dispensing systems that can help them increase efficiency, accuracy and safety in their operations.

Customers & Cohorts

As part of this competitive intelligence study, we have identified the main customers of the organisation.

These include the following cohorts:

Hospitals
Care Homes
Retail Pharmacies
Pharmaceutical Manufacturers
Private Healthcare Providers
Community Pharmacies
Wholesalers
Clinics
Veterinary Practices
Laboratories

Market Trends

Market trends can impact an organisation by influencing consumer behavior, altering supply and demand dynamics, and affecting the organisation's ability to remain competitive in the market.

As part of this study, we have identified a number of potential short-term to medium-term trends that could impact the organisation. These include the following:

Expansion of Online Retail: With the rise of e-commerce, Uniphar Plc must focus on the expansion of its online presence in order to remain competitive in the marketplace. As online retail continues to grow, Uniphar Plc must ensure it has the resources and technology to meet the increasing demand for online purchases.

Growth of Specialty Products: Consumers are increasingly seeking out specialty products and Uniphar Plc must focus on providing these types of products. Uniphar Plc must focus on providing a wide range of specialty products to meet the changing needs of consumers.

Increased Focus on Sustainability: As consumers become increasingly aware of their environmental impact, Uniphar Plc must focus on providing sustainable products. Uniphar Plc must focus on reducing its environmental impact and providing greener products that meet the needs of consumers.

Shift to Digital Payments: With the rise of digital payment methods, Uniphar Plc must ensure it is able to accept digital payments. Uniphar Plc must focus on providing payment options that meet the needs of consumers, such as mobile payments and cryptocurrency.

Key Performance Indicators

Below is a list of KPI's that we have identified as being strategically relevant to this organisation:

Financials (BETA)

The key financials for Uniphar Plc include income statements, which can be found in their annual reports. These financial statements provide information on the organisation's financial performance and health, including revenue, expenses, and profits. This information, along with other indicators are used by investors, analysts and other stakeholders to evaluate the company's performance and future prospects.

Where a financial does not match, we have included those of the parent company (if a listed entity). If the financials are missing please contact us and we will prioritise the update.

Key Personnel

Income Statement

[eod_financials target="UPR.IR" id="10329343" preset="Income Statement" years="2018-2023"]

Highlights

Top-level corporate stats and financial highlights for the listed entity, include:

Share Performance

Below is the current (EOD) share performance for the company, or its listed parent:

Potential Products/Services

As part of this study we have attempted to prognosticate potential products and/or services this organisation could develop in the short to medium-term.

Online ordering system: Uniphar Plc could create an online ordering system to allow customers to easily purchase products and/or services from their website or mobile app.

Delivery service: Uniphar Plc could create a delivery service to help customers get their orders to their doorstep quickly and with minimal hassle.

Loyalty program: Uniphar Plc could create a loyalty program to reward customers for their repeat purchases.

Online customer support: Uniphar Plc could create an online customer support system to help customers with any questions or issues they may have.

Customised solutions: Uniphar Plc could create customized solutions for customers to help them optimize their purchasing experience.

Mobile application: Uniphar Plc could create a mobile application to provide customers with easy access to their products and services.

Training and education: Uniphar Plc could create training and education programs to help customers stay up-to-date on the latest products and services.

Potential Synergies

Using our product and portfolio-matching algorithm, we have determined that the following organisations have potential synergies with the company:

1. Hospitals
2. Clinics
3. Pharmacies
4. Supermarkets
5. Pharmaceutical wholesalers
6. Pharmaceutical manufacturers
7. Health care organisations
8. Medical device companies
9. Retailers
10. Distributors

Porter's Five Forces

Created by Harvard Business School Professor Michael Porter in 1979, Porter's Five Forces model is designed to help analyse the particular attractiveness of an industry; evaluate investment options; and better assess the competitive environment.

The five forces are as follows:

Competitive rivalry
Supplier power
Buyer power
Threat of substitution
Threat of new entries

The Porters 5 forces for Uniphar Plc are as follows:

1. Supplier power: HIGH

2. Buyer power: LOW

3. Threat of new entrants: LOW

4. Threat of substitutes: MEDIUM

5. Rivalry among existing competitors: MEDIUM

Uniphar Plc scores relatively WELL in relation to the Porters 5 forces. The company has HIGH supplier power, but this is offset by LOW buyer power and LOW threat of new entrants. The company also has a MEDIUM threat of substitutes and a MEDIUM level of rivalry among existing competitors.

PESTLE Analysis

This PESTLE analysis is a strategic planning tool that assesses key external factors affecting the organisation, including the following:

Political
Economic
Social
Technological
Legal
Environmental

Each of these factors is analysed to determine their impact on the organisations strategy, objectives, and operations.

By utilising a PESTLE analysis, the organisation can make better decisions and develop strategies to address potential risks and opportunities.

CATWOE Analysis

The CATWOE analysis is used to investigate each stakeholders perspectives in order to enable the business to make informed decisions.

The CATWOE analysis is a problem-solving tool consisting of six elements:

Customers
Actors
Transformation process
World view
Owners
Environmental constraints

We view the CATWOE as being most useful when used in conjunction with other problem-solving tools such as a SWOT analysis.

Customers: Uniphar Plc provides products, services and solutions for customers in the healthcare, retail and industrial sectors. The customers are primarily healthcare organisations, such as hospitals and pharmacies, retailers, and industrial companies.

Actors: Uniphar Plc has a wide range of actors involved in the business, including employees, suppliers, health and safety consultants, customers, government agencies and regulators.

Transformation process: Uniphar Plc’s transformation process involves providing customers with tailored solutions and services that meet their needs. This includes offering innovative products, services, and solutions that are tailored to customers’ needs, as well as providing efficient and cost-effective supply chain solutions.

World view: Uniphar Plc’s world view is focused on providing customers with high-quality products, services, and solutions that meet their needs. The company strives to build long-term relationships with customers and to be a trusted partner in healthcare, retail and industrial sectors.

Owners: Uniphar Plc is a publicly traded company, with shareholders being its main owners.

Environmental constraints: Uniphar Plc is subject to various environmental constraints, such as government regulations, the industry’s competitive environment, and the changing needs of customers. The company must ensure that its products, services, and solutions meet regulatory requirements, are cost-effective and provide a competitive advantage.

SWOT Analysis

This SWOT analysis is a strategic planning tool used to assess the strengths, weaknesses, opportunities and threats of the Uniphar Plc business.

When creating this SWOT the team at Platform Executive have taken into consideration the corporate strategy; brand; key financials; the competitive landscape; along with the products and/or services offered.

To offer increased context for future innovation and product development we also consider the historical context for the business and industry; and perceived direction of travel.

Upon researching the company, we have uncovered a number of strategic and operational strengths, weaknesses, opportunities and threats.

Strengths

Below is a list of the strengths we have identified for the business:

1. Uniphar has a strong focus on customer service, with a dedicated team of customer service professionals who are available 24/7 to help with any enquiries or orders.

2. Uniphar has an extensive range of products and services, with over 200,000 products available to order.

3. Uniphar has an excellent reputation in the industry, with over 50 years’ experience in providing healthcare and pharmaceutical products and services.

4. Uniphar has a strong commitment to quality, with ISO 9001:2008 certification across all of its operations.

Opportunities

Below is a list of opportunities we have identified for the business:

1. Optimize operational efficiency by introducing process automation and robotics technology: This will enable Uniphar Plc to reduce operational costs and increase operational speed and accuracy.

2. Strengthen relationships with existing customers: Uniphar Plc should focus on developing strong customer relationships through offering tailored services and building loyalty programs.

3. Expand into new markets: Uniphar Plc should focus on entering new markets by offering innovative products and services that meet the needs of the target markets.

4. Invest in technology: Uniphar Plc should invest in the latest technology to enhance customer experience, improve operational efficiency, and provide competitive advantages. This can include investing in analytics and data-driven insights, cloud-based solutions, and mobile applications.

Weaknesses

Below is a list of the weaknesses we have identified for the business:

1. Lack of focus: Uniphar plc has been trying to diversify its business in recent years, but this has led to a lack of focus on its core operations.

2. Poor execution: Uniphar has been struggling to execute its plans effectively, resulting in missed targets and disappointing results.

3. High costs: Uniphar's costs are relatively high compared to its peers, which has put pressure on its margins.

4. Dependence on the Irish market: Uniphar is heavily dependent on the Irish market, which makes it vulnerable to economic fluctuations in that country.

Threats

Below is a list of the threats we have identified for the business:

1. Increasing Competition: Uniphar Plc is facing increasing competition from other healthcare providers in the market. This could lead to a decrease in market share, resulting in lower profitability.

2. Changes in Technology: The healthcare industry is rapidly changing, and Uniphar Plc needs to be able to keep up with the latest technologies and trends. Failure to do so could lead to the company being left behind, resulting in a decrease in profits.

3. Regulatory Changes: Changes in healthcare regulations can lead to increased costs and decreased profits for Uniphar Plc. The company needs to be able to anticipate and adapt to changes in the regulatory environment in order to remain competitive.

4. Financial Risk: Uniphar Plc is exposed to financial risk due to its reliance on debt and equity financing. The company needs to manage its debt and equity responsibly in order to ensure that it has sufficient financing for operations and growth.

5C Analysis

The 5C Analysis is a marketing framework that can be used to provide insight into the key drivers of success, as well as the risk exposure to various environmental factors.

This (concise) 5C analysis examines the external and internal environment for Uniphar Plc. It includes analysing the company's customers, competitors, collaborators, context, and capabilities. We have produced this short analysis to identify potential opportunities and threats to Uniphar Plc, as well as areas where the company needs to improve its operations or strategy.

Company: Uniphar Plc is an Irish-based pharmaceutical and healthcare logistics company. It is the leading provider of healthcare and pharmaceutical services in Ireland and the UK.

Collaborators: Uniphar Plc works closely with healthcare providers, manufacturers and suppliers to ensure the highest quality of care and product availability. It has strategic partnerships with leading manufacturers and suppliers to provide customers with a wide range of products.

Customers: Uniphar Plc’s customers include doctors, hospitals, pharmacies and other healthcare providers. It also provides services to pharmaceutical companies, wholesalers, retailers and the general public.

Competitors: Uniphar Plc has many competitors in the healthcare and pharmaceutical industry, including other logistics companies, wholesalers and retailers.

Content: Uniphar Plc provides a wide range of services, including supply chain management, distribution, e-commerce, customer service, and more. It also offers innovative products and services, such as its online ordering platform, which allows customers to order products quickly and easily.

MOST Analysis

The MOST analysis framework is commonly used to identify an organisation's strategic goals, assess its strengths and weaknesses, and develop a plan to achieve its objectives. This analysis helps organisations to focus on what they want to achieve and how to achieve it, while also identifying potential roadblocks or obstacles that may arise along the way.

Mission
Objectives
Strategy
Tactics

We have created this analysis from a 3rd person perspective.

Innovation Scorecard

As part of our research and analysis activity, the team at Platform Executive assesses and then benchmarks businesses and the industry verticals in which they operate using a proprietary scoring mechanism.

First, we allocate a score of A-E for the industry vertical, gauged on the key organisations operating within the space; and then score the individual business using a 1-5 score.

A score of D-E within an industry means that it is potentially ripe to be disrupted by a new entrant into the marketplace; and/or vulnerable to technological change.

Likewise, a high score of 4-5 for the company in question indicates that in the view of the analysis team it lags behind notable businesses in terms of innovation and product pipeline.

Below is a guide to each score:

Industry score:

A	The industry is amongst the most innovative; with the leading players all driving the sector forward. Example industry: PaaS
B	The industry and its leading players have a good track record of innovation; and can quickly react to change. Example industry: Pharmaceutical
C	Companies operating within the sector have adequate levels of innovation; and engage in R&D activities when appropriate. Example industry: FMCG
D	Businesses operating in the industry do not invest enough time and resource into innovation. The sector is stagnant and a good candidate for disruption. Example industry: Retail Banking
E	The major players in the sector seem to lack suitable product development roadmaps; and as a result the sector is highly vulnerable to industry change. Example industry: Publishing

Company score:

1	The business is amongst the leading players in terms innovation and product pipeline. This will fulfil and reinforce the operations of the business in the medium to long-term.
2	The business has a good track record of innovation, in terms of its products and/or its business model. It is therefore more likely to be able to react and adapt to any changes to the industry.
3	The business is deemed to have an adequate innovation plan, build on research and development and sustainability where appropriate. The business has a product development strategy.
4	The business needs to invest more resource and/or intellectual capital in product development, pipelines and/or its business model. The business is at risk of stagnation.
5	The business seems to lack a suitable product development roadmap; and as a result is vulnerable to any notable industry change and/or new entrants in the marketplace.

The team at Platform Executive has judged Uniphar Plc as having an innovation score of C3.

Appendices

The appendices section of this report contains supplementary information that the team at Platform Executive deems helpful in providing a more comprehensive understanding of the report's contents.

This information is not considered an essential part of the study but serves as a useful supplement to the main text.

Methodology

This study on Uniphar Plc forms part of our series of competitive intelligence reports, which focuses on 10,000 of the largest corporates.

The information and data included are updated on a timely schedule to ensure that our Premium members receive the most up to date information .

The report is based on information and learning from the following sources:

Corporate websites
Proprietary research databases
SEC Filings
Corporate press releases
News articles
Financial data API's
Product-matching algorithm

Further Information

Premium members: If you cannot find the desired information or data set for the business you are researching then please reach out to our research and analysis team. We can tailor reports to meet your requiremnents, with a fast turnaround time.

If you require a bespoke study on a particular industry vertical, or marketplace we may also be able to help.

Disclaimer

Reproduction of the content produced in this report is prohibited without the prior permission of the publisher, Platform Executive Pty Ltd.

The facts of this report have been gathered in good faith from both primary and secondary sources. It is believed to be correct at the time of publication, but cannot be guaranteed. As such Platform Executive can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.

Changelog

Premium members: To request a priority update to this report, please contact us. Our standard turnaround time is normally 48 hours.

The changelog for this report can be found below, complete with the next scheduled update:

v1.1: Initial load of report
Date: 1st March 2023

Key Financials added (BETA)
Date: 17th March 2023

Next scheduled update: 29th May 2023

Industry Keywords

Related keywords:

Distribution Healthcare logistics Pharmaceuticals

The Trade Desk Inc

Universal Logistics Holdings Inc